Propafenone is a highly effective and safe antiarrhythmic agent with a low incidence of side effects. It is widely
used in treatment of a variety of cardiac arrhythmias, particularly in prophylaxis of supraventricular tachycardias,
especially atrial fibrillation (Afib) and atrial flutter (AFL). It is also effective in reducing the incidence of subjective
negative perception of ventricular extrasystoles (VES). Better pharmacokinetic and pharmacodynamic
properties allow increase in the antiarrhythmic efficacy of propafenone with extended release confirmed in large
clinical studies. It has led to almost complete replacement of short acting propafenone by modern extended release
tablets. This second part of the review article about properties and efficacy of propafenone presents available
evidence on the therapeutic use of propafenone as well as pharmacovigilance aspects in clinical practice.